Evidence map›Paper›PMID 29576851›Full record

ArticleOxidative medicine and cellular longevity2018

Autophagy Stimulus Promotes Early HuR Protein Activation and p62/SQSTM1 Protein Synthesis in ARPE-19 Cells by Triggering Erk1/2, p38

Nicoletta Marchesi, Natthakan Thongon, Alessia Pascale, Alessandro Provenzani, Ali Koskela, Eveliina Korhonen, Adrian Smedowski, Stefano Govoni, Anu Kauppinen, Kai Kaarniranta and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Guideline
  2. Different Therapeutic Approaches for Dry and Wet AMD.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. mAutophagy · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Frontiers in pharmacology · 2020
    Article
  15. Frontiers in immunology · 2020
    Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Nicoletta MarchesiDepartment of Drug Sciences, Pharmacology Section, University of Pavia, 27100 Pavia, Italy.
Natthakan ThongonLaboratory of Genomic Screening, Center for Integrative Biology, University of Trento, 38123 Trento, Italy.
Alessia PascaleDepartment of Drug Sciences, Pharmacology Section, University of Pavia, 27100 Pavia, Italy.
Alessandro ProvenzaniLaboratory of Genomic Screening, Center for Integrative Biology, University of Trento, 38123 Trento, Italy.
Ali KoskelaDepartment of Ophthalmology, University of Eastern Finland, 70211 Kuopio, Finland.
Eveliina KorhonenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.
Adrian SmedowskiChair and Department of Physiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.ORCID 0000-0001-8528-955X
Stefano GovoniDepartment of Drug Sciences, Pharmacology Section, University of Pavia, 27100 Pavia, Italy.
Anu KauppinenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.ORCID 0000-0001-8254-0200
Kai KaarnirantaDepartment of Ophthalmology, University of Eastern Finland, 70211 Kuopio, Finland.
Marialaura AmadioDepartment of Drug Sciences, Pharmacology Section, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0001-5263-9306
University of Eastern Finland · FIUniversity of Pavia · ITUniversity of Trento · ITMedical University of Silesia · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA-binding protein dysregulation and altered expression of proteins involved in the autophagy/proteasome pathway play a role in many neurodegenerative disease onset/progression, including age-related macular degeneration (AMD). HuR/ELAVL1 is a master regulator of gene expression in human physiopathology. In ARPE-19 cells exposed to the proteasomal inhibitor MG132, HuR positively affects at posttranscriptional level p62 expression, a stress response gene involved in protein aggregate clearance with a role in AMD. Here, we studied the early effects of the proautophagy AICAR + MG132 cotreatment on the HuR-p62 pathway. We treated ARPE-19 cells with Erk1/2, AMPK, p38

Indexed as

MAP Kinase Signaling SystemAutophagyCell LineELAV-Like Protein 1HumansMAP Kinase Kinase 4p38 Mitogen-Activated Protein KinasesRetinal Pigment EpitheliumSequestosome-1 ProteinELAVL1 protein, humanELAV-Like Protein 1MAP Kinase Kinase 4p38 Mitogen-Activated Protein KinasesSequestosome-1 ProteinSQSTM1 protein, human

Identifiers

PMID29576851
PMCPMC5822911
OpenAlexW2788703149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.